Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001831749-26-000002
Filing Date
2026-02-02
Accepted
2026-02-02 16:01:11
Documents
2
Period of Report
2026-01-30

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 4150
2 SECTION 16 POA- BELLON bellonex24.txt EX-24 3552
  Complete submission text file 0001831749-26-000002.txt   9168
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Issuer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address
Bellon Steven F. (Reporting) CIK: 0001831749 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39634 | Film No.: 26587740